Author

María José Lallena

Eli Lilly (Spain)ORCID 0000-0002-6617-798XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:protein structure prediction· 1 Approach:statistical model· 1

Frequent Co-Authors

Alicia Alonso de la VegaiD· 1 shared Ana Monfort‐VengutiD· 1 shared Ana Teijo· 1 shared Beatriz Ortigosa· 1 shared Carlos MarugániD· 1 shared Cristina Bertinetti· 1 shared Gema Moreno‐BuenoiD· 1 shared Guillermo de CárceriD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alicia Alonso de la VegaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyMolecular OncologyPeer-reviewedFeb 15, 2024

TPX2 expression promotes sensitivity to dasatinib in breast cancer by activating the YAP transcriptional signaling.

Carlos Marugán, Natalia Sanz‐Gómez, Beatriz Ortigosa…·Guillermo de Cárcer

The paper identifies TPX2 as a gene that increases breast cancer sensitivity to dasatinib by activating the YAP pathway, and shows TPX2 and YAP are biomarkers for poor prognosis and potential dasatinib therapy.

9 citations

humanbulk RNA-seq

𝕏 PostBluesky